MeiraGTx Holdings plc - Ordinary Shares (MGTX)
MGTX moved a median of -0.10% 30 minutes after news, and -0.83% by the close. How MGTX actually reacts to news — the realized, point-in-time move the market made, measured across 239 labeled events over the last three years with zero look-ahead.
MGTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 238 |
| 30-min | -0.10% | 46% | 239 |
| 60-min | +0.16% | 50% | 239 |
| to close | -0.83% | 44% | 235 |
| Middle 50% of MGTX reactions | -1.81% to +1.00% |
|---|---|
| Median reaction (30-min) | -0.10% |
| Measured reactions | 239 |
Half of all MeiraGTx Holdings plc - Ordinary Shares news events land between -1.81% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when MGTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MGTX's baseline. Nothing else.
Recent MGTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MeiraGTx Holdings plc For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -4.16% | |
| MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors | Press release | GlobeNewswire | -0.53% | -4.16% | |
| Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical | Press release | PR Newswire | -0.14% | -0.27% | |
| Form 10-Q MeiraGTx Holdings plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.61% | -10.71% | |
| Form 8-K MeiraGTx Holdings plc For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -2.61% | -10.71% | |
| Form S-8 MeiraGTx Holdings plc | SEC filing · Form S-8 | SEC EDGAR | -2.61% | -10.71% | |
| MeiraGTx Reports Second Quarter 2026 Financial and Operational Results | Press release | GlobeNewswire | -2.61% | -10.71% | |
| Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia | Press release | PR Newswire | +0.31% | +1.56% | |
| MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.54% | +0.38% | |
| Form 8-K MeiraGTx Holdings plc For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | +9.98% | |
| MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) | Press release | GlobeNewswire | +0.68% | +9.98% | |
| Form 8-K MeiraGTx Holdings plc For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | -0.92% | |
| Form 10-Q MeiraGTx Holdings plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.40% | -0.30% | |
| Form 8-K MeiraGTx Holdings plc For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -0.30% | |
| MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -4.86% | |
| MeiraGTx Reports First Quarter 2026 Financial and Operational Results | Press release | GlobeNewswire | -1.40% | -0.30% | |
| Form ARS MeiraGTx Holdings plc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.00% | +2.33% | |
| Form DEF 14A MeiraGTx Holdings plc For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +1.00% | +2.33% | |
| Form DEFA14A MeiraGTx Holdings plc | SEC filing · Form DEFA14A | SEC EDGAR | +1.00% | +2.33% | |
| Form 8-K MeiraGTx Holdings plc For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | -2.02% | |
| Form 8-K MeiraGTx Holdings plc For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -4.71% | -0.73% | |
| Form 8-K MeiraGTx Holdings plc For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -4.71% | -0.73% | |
| MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia | Press release | GlobeNewswire | -4.71% | -0.73% | |
| MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares | Press release | GlobeNewswire | +1.57% | +2.38% | |
| MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 | Press release | GlobeNewswire | +5.32% | +15.44% | |
| Form 10-K MeiraGTx Holdings plc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.16% | +9.32% | |
| Form 8-K MeiraGTx Holdings plc For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | -1.44% | |
| MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results | Press release | GlobeNewswire | +1.64% | -1.44% | |
| ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy | Press release | PR Newswire | +0.82% | +1.77% | |
| Form 8-K MeiraGTx Holdings plc For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | -1.88% | |
| Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference | Press release | PR Newswire | -1.05% | -2.11% | |
| Form 10-Q MeiraGTx Holdings plc For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.63% | — | |
| Form 8-K MeiraGTx Holdings plc For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | — | |
| MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Press release | GlobeNewswire | +1.63% | — | |
| Form 8-K MeiraGTx Holdings plc For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +2.20% | -6.04% | |
| MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology | Press release | GlobeNewswire | +2.20% | -6.04% | |
| MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress | Press release | GlobeNewswire | -0.06% | +1.07% | |
| Form 10-Q MeiraGTx Holdings plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.29% | -3.03% | |
| Form 8-K MeiraGTx Holdings plc For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | +1.71% | |
| MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | Press release | GlobeNewswire | -1.36% | +1.71% | |
| Form 8-K MeiraGTx Holdings plc For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | +2.93% | |
| Form 8-K MeiraGTx Holdings plc For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -2.28% | -3.65% | |
| Form 10-Q MeiraGTx Holdings plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.62% | -8.20% | |
| Form 8-K MeiraGTx Holdings plc For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.62% | -8.20% | |
| MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting | Press release | GlobeNewswire | -0.98% | -9.12% | |
| MeiraGTx Reports First Quarter 2025 Financial and Operational Results | Press release | GlobeNewswire | +0.62% | -8.20% | |
| Form 8-K MeiraGTx Holdings plc For: May 09 | SEC filing · Form 8-K | SEC EDGAR | -7.57% | -5.74% | |
| MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease | Press release | GlobeNewswire | -7.57% | -5.74% | |
| Form ARS MeiraGTx Holdings plc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.69% | +4.42% | |
| Form DEF 14A MeiraGTx Holdings plc For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | +0.69% | +4.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MGTX section they belong to.
Where else MGTX is measured.
MGTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | 239 | 0.00% | 41% |
| Lixte Biotechnology Holdings, Inc. (LIXT) | 239 | 0.00% | 48% |
| Ovid Therapeutics Inc. (OVID) | 239 | -0.32% | 40% |
| Cyclacel Pharmaceuticals, Inc. (CYCC) | 238 | -0.21% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MeiraGTx Holdings plc - Ordinary Shares's median reaction calculated?
Every labeled MGTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 239 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of MGTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MGTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.